ArticleAnnals of medicine and surgery (2012)2026
Advances in pharmacologic management of obesity: oral semaglutide for weight management.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a chronic, multifactorial disease characterized by excessive adiposity and associated with an increased risk of cardiovascular disease, type 2 diabetes, and reduced quality of life. Despite the widespread adoption of lifestyle interventions, long-term weight maintenance remains challenging, highlighting the need for effective pharmacologic therapies. Recent advances, including the US Food and Drug Administration approval of oral semaglutide, offer new opportunities for patient-centered obesity management. Evidence from the OASIS 1 and OASIS 4 trials demonstrates that oral semaglutide, combined with lifestyle intervention, produces clinically meaningful weight loss in adults with overweight or obesity without type 2 diabetes, while improving physical function and cardiometabolic risk markers, such as waist circumference, lipids, and inflammatory parameters. These trials further underscore the benefits of an oral formulation in improving accessibility and adherence compared with injectable therapies. Collectively, oral semaglutide represents a significant advancement in obesity pharmacotherapy, complementing lifestyle interventions and providing both metabolic and functional benefits. Future studies addressing long-term efficacy, cardiovascular outcomes, comparative effectiveness with other agents, and real-world implementation will be essential to fully define its role in comprehensive, individualized obesity care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.